University of Illinois at Chicago
Exemption #JDR406
Announcement of an Exempt Purchase
Award Info Published Thursday November 21, 2024
Advanced Accelerator Applications USA IncEast Hanover, NJ
- Amount: An estimated $990,000
- Terms: An estimated start date of 11/21/2024 through 2/1/2025
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Thursday, November 21, 2024
The University awarded a contract for radiopharmaceuticals.
This purchase is for the radiopharmaceuticals Pluvicto and Lutetium. Lutetium Lu-177 dotatate, is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The Pluvicto Lu-177 is indicated for the treatment for patients with Prostate Specific Membrane Antigen-Positive metastatic castration- resistant prostate cancer.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical at a university-operated health care center or dispensary that provides care, treatment, and medications for students, faculty and staff (30 ILCS 500 / 1-13(b-5)) Without these radiopharmaceuticals, UIH will not be able to provide care for the patients, and will lose revenue.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.